{"doi":"10.1101/2024.03.29.587381","title":"Recharacterization of RSL3 reveals that the selenoproteome is a druggable target in colorectal cancer","abstract":"Abstract Ferroptosis is a non-apoptotic form of cell death resulting from the iron-dependent accumulation of lipid peroxides. Colorectal cancer (CRC) cells accumulate high levels of intracellular iron and reactive oxygen species (ROS) and are thus particularly sensitive to ferroptosis. The compound (S)-RSL3 ([1S,3R]-RSL3) is a commonly used ferroptosis inducing compound that is currently characterized as a selective inhibitor of the selenocysteine containing enzyme (selenoprotein) Gluathione Peroxidase 4 (GPx4), an enzyme that utilizes glutathione to directly detoxify lipid peroxides. However, through chemical controls utilizing the (R) stereoisomer of RSL3 ([1R,3R]-RSL3) that does not bind GPx4, combined with inducible genetic knockdowns of GPx4 in CRC cell lines, we revealed that GPx4 dependency does not always align with (S)-RSL3 sensitivity, questioning the current characterization of GPx4 as the central regulator of ferroptosis. Utilizing affinity pull-down mass spectrometry with chemically modified (S)-RSL3 probes we discovered that the effects of (S)-RSL3 extend far beyond GPx4 inhibition, revealing that (S)-RSL3 is a broad and non-selective inhibitor of selenoproteins. To further investigate the therapeutic potential of broadly disrupting the selenoproteome as a therapeutic strategy in CRC, we employed additional chemical and genetic approaches. We found that the selenoprotein inhibitor auranofin, an FDA approved gold-salt, chemically induced oxidative cell death and ferroptosis in both in-vitro and in-vivo models of CRC. Consistent with these data, we found that AlkBH8, a tRNA-selenocysteine methyltransferase required for the translation of selenoproteins, is essential for the in-vitro growth and xenograft survival of CRC cell lines. In summary, these findings recharacterize the mechanism of action of the most commonly used ferroptosis inducing molecule, (S)-RSL3, and reveal that broad inhibition of selenoproteins is a promising novel therapeutic angle for the treatment of CRC.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2024,"id":484334,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9569,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1311299,"name":"Liang Zhao","orcid":"0009-0004-5999-8976","position":1,"is_corresponding":false},{"id":1250912,"name":"Sofia Dziechciarz","orcid":"0009-0001-8843-0691","position":2,"is_corresponding":false},{"id":505671,"name":"Myungsun Shin","orcid":null,"position":3,"is_corresponding":false},{"id":619220,"name":"Sumeet Solanki","orcid":"0000-0002-2773-3082","position":4,"is_corresponding":false},{"id":529153,"name":"Andrii Balia","orcid":null,"position":5,"is_corresponding":false},{"id":843761,"name":"Marwa O. El-Derany","orcid":"0000-0002-1552-9607","position":6,"is_corresponding":false},{"id":1041872,"name":"Cristina Castillo","orcid":"0000-0003-1323-6875","position":7,"is_corresponding":false},{"id":291801,"name":"Yao Qin","orcid":"0000-0001-9880-7301","position":8,"is_corresponding":false},{"id":619219,"name":"Nupur K. Das","orcid":"0000-0002-5652-1134","position":9,"is_corresponding":false},{"id":619216,"name":"Hannah N. Bell","orcid":"0000-0003-2609-5557","position":10,"is_corresponding":false},{"id":136624,"name":"Joao A. Paulo","orcid":"0000-0002-4291-413X","position":11,"is_corresponding":false},{"id":1326012,"name":"Yuezhong Zhang","orcid":"0000-0002-0580-9939","position":12,"is_corresponding":false},{"id":1326534,"name":"Nicholas Rossiter","orcid":null,"position":13,"is_corresponding":false},{"id":1285174,"name":"Elizabeth C. McCulla","orcid":"0009-0003-2583-0094","position":14,"is_corresponding":false},{"id":242716,"name":"Jianping He","orcid":"0009-0001-6177-4179","position":15,"is_corresponding":false},{"id":1041871,"name":"Indrani Talukder","orcid":"0000-0002-4144-3815","position":16,"is_corresponding":false},{"id":488738,"name":"Wai‐Lung Ng","orcid":"0000-0003-2892-6318","position":17,"is_corresponding":false},{"id":993391,"name":"Zachary T. Schafer","orcid":"0000-0001-9227-3118","position":18,"is_corresponding":false},{"id":248975,"name":"Nouri Neamati","orcid":"0000-0003-3291-7131","position":19,"is_corresponding":false},{"id":237057,"name":"Joseph D. Mancias","orcid":"0000-0002-0692-3717","position":20,"is_corresponding":false},{"id":418435,"name":"Markos Koutmos","orcid":"0000-0003-0933-6312","position":21,"is_corresponding":false},{"id":432386,"name":"Yatrik M. Shah","orcid":"0000-0002-2487-4816","position":22,"is_corresponding":false},{"id":1037754,"name":"Stephen L. DeAngelo","orcid":"0000-0002-7984-5780","position":0,"is_corresponding":true}],"reference_count":66,"raw_metadata":null,"created_at":"2026-07-19T02:07:38.055693Z","pmid":"38617233","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}